Scribd
Upload
90 views

Sec Form 4 10

Mitchel Sayare, a director of Pharmathene, Inc., received stock options for 112,139 shares as part of his compensation. The options have an exercise price of $2.67 per share, which was the stock price on the date of grant. One-third of the 60,000 share option vests immediately, and the remaining two-thirds vest annually over the next two years. The 52,139 share option vests quarterly over the next three years starting in October 2011.

Uploaded by

Anonymous Feglbx5
Copyright
© Attribution Non-Commercial (BY-NC)
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
90 views

Sec Form 4 10

Mitchel Sayare, a director of Pharmathene, Inc., received stock options for 112,139 shares as part of his compensation. The options have an exercise price of $2.67 per share, which was the stock price on the date of grant. One-third of the 60,000 share option vests immediately, and the remaining two-thirds vest annually over the next two years. The 52,139 share option vests quarterly over the next three years starting in October 2011.

Uploaded by

Anonymous Feglbx5
Copyright
© Attribution Non-Commercial (BY-NC)
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
You are on page 1/ 1

7/20/2011 SEC Form 4

SEC FORM 4

FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549

OMB APPROVAL
OMB Number: Expires: 3235-0287 Nov ember 30, 2011

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP


Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 2. Issuer Name and T icker or T rading Symbol

Estimated av erage burden hours per response: 0.5

1. Name and Address of Reporting Person *

SAYARE MITCHEL
(Last) (First) (Middle)

PHARMATHENE, INC [ PIP ]


3. Date of Earliest Transaction (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

X 07/15/2011
4. If Amendment, Date of Original Filed (Month/Day/Year)

Director Officer (give title below)

10% Owner Other (specify below)

C/O PHARMATHENE, INC., ONE PARK PLACE, SUITE 450


(Street)

6. Individual or Joint/Group Filing (Check Applicable Line)

X ANNAPOLIS
(City)

Form filed by One Reporting Person Form filed by More than One Reporting Person

MD
(State)

21401
(Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned


1. Title of Security (Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) Code V 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)

Amount

(A) or (D)

Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Stock option (right to buy) Stock option (right to buy)

$2.67

07/15/2011

60,000

(1)

07/15/2021

Common Stock

60,000

(2)

60,000

$2.67

07/17/2011

52,139

(3)

07/17/2021

Common Stock

52,139

(2)

52,139

Explanation of Responses: 1. One-third of the option vests immediately, and one-third of the option vests on each of the second and third anniversaries of the grant date. 2. On July 15, 2011, the trading day on which, or immediately preceding the day on which, the stock options were granted, the closing price of the Issuer's common stock was $2.67 per share. 3. T he option vests in equal quarterly installments over three years commencing on October 15, 2011.

/s/ Roland S. Chase, as attorney-in-fact


** Signature of Reporting Person Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

07/19/2011
Date

Persons w ho respond to the collection of information contained in this form are not required to respond unless the form displays a currently v alid OMB Number.

PDF created with pdfFactory trial version www.pdffactory.com

sec.gov/Archives//v229068_ex.xml

1/1

You might also like

pFad - Phonifier reborn

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.

Note: This service is not intended for secure transactions such as banking, social media, email, or purchasing. Use at your own risk. We assume no liability whatsoever for broken pages.


Alternative Proxies:

Alternative Proxy

pFad Proxy

pFad v3 Proxy

pFad v4 Proxy